(December 2, 2016, 1:43 PM EST) -- WASHINGTON, D.C. — AstraZeneca AB argues in a Nov. 21 opposition brief that the U.S. Supreme Court should decline to answer whether the filing of an abbreviated new drug application (ANDA) is sufficient to subject Mylan Pharmaceuticals Inc. and Mylan Inc. (collectively, Mylan) to specific personal jurisdiction in any state where they might market the drug (Mylan Pharmaceuticals Inc., et al. v. Acorda Therapeutics Inc., et al. & Mylan Pharmaceuticals Inc. v. AstraZeneca AB, No. 16-360, U.S. Sup.)....